Nouscom Poster presentation at SITC 2021
Nouscom Poster presentation at SITC 2021, reporting interim Phase 1 results on Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in [...]
Nouscom Poster presentation at ESMO 2021
Nouscom Poster presentation at ESMO 2021, reporting the first clinical dataset from the Phase 1 trial of NOUS-209, an off-the-shelf cancer vaccine based on shared neoantigens, in combination with [...]
Nouscom AG: Poster on initial results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at ESMO
Our abstract “Initial Results from a Phase I Study of NOUS-209, an Off-the-Shelf Viral Vectored Immunotherapy Encoding 209 Shared Frame Shift Peptide Neoantigens, with Pembrolizumab, for the [...]
